Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2003-05-14
2008-12-02
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252010, C514S252030, C544S238000, C544S239000
Reexamination Certificate
active
07459453
ABSTRACT:
New pyridazin-3(2H)-one derivatives having the chemical structure of general formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of phosphodiesterase 4.
REFERENCES:
patent: 5804588 (1998-09-01), Dyke et al.
patent: 5859008 (1999-01-01), Jonas et al.
patent: 5972936 (1999-10-01), Dyke et al.
patent: 6162830 (2000-12-01), Connor et al.
patent: 6204275 (2001-03-01), Friesen et al.
patent: 6699890 (2004-03-01), Schumacher et al.
patent: 405344 (1975-08-01), None
patent: WO93/07146 (1993-04-01), None
patent: WO01/94319 (2001-12-01), None
Lipworth, Lancet 2005, 365: 167-75.
MacKenzie, Phosphodiesterase 4 cAMP phosphodiesterases as targets for novel anti-inflammatory therapeutics, Alergology International (2004) 53: 101-110.
Griffiths, et al., British J. of Dermatology 2002: 147, 299-307.
Wikipedia, Phosphodiesterase, <http://en.wikipediaa.org/wiki/Phosphodoesterase>, downloaded May 31, 2007.
Wikipedia, COPD, <http://en.wikipedia.org/wiki/COPD>, downloaded May 30, 2007.
Wikipedia,Inflammatory Bowel Disease, <http://en.wikipedia.org/wiki/IBD>, downloaded May 31, 2007.
Spina, Drugs, 2003, 63, 23, pp. 2575-2594.
Baumer, et al., Inflammation & Allergy—Drug Targets, vol. 6, No. 1, Mar. 2007.
Implications for Rheumatoid Arthritis http://www.medscape.com/viewarticle/464104—4, downloaded Jul. 8, 2007.
Phosphodiesterases: A Drug Target Family with Broad Therapeutic Impact, http://www.piribo.com/publications/drug—discovery/DMD054.html, downloaded Jul. 9, 2007.
Dr. Andrew R. Marks, Columbia University Medical Center press release, Drugs in Trials for Asthma, Alzheimer's and Chronic Lung Disease May Cause Heart Disease, < http://www.cumc.columbia.edu
ews/press—releases/Marks—Cell.html>, downloaded Jul. 9, 2007.
Vittorio Dal Piaz et al.; J. of Pharmaceutical Sciences, 1991, V.80, N.4, pp. 341-348.
Luca Costantino et al.; J. Med. Chem., 1999, N.42, pp. 1894-1900.
Giovanna Ciciani et al.; Il Farmaco, 1991, V.46. N.7-8, pp. 873-885.
Daniela Barlocco et al.; J. Med. Chem., 2001, N.44, pp. 2403-2410.
Vittorio Dal Piaz et al.; Eur. J. Med. Chem.; 1996, N.31, pp. 65-70.
Margaretha Van Der Mey et al.; J. Med, Chem.; 2001, N. 44, pp. 2511-2522.
CAPLUS abstract for SU 405344, accession No. 1976:4988 dated May 12, 1984.
Essayan, David M., “Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation,” Biochemical Pharmacology, 57:965-973 (1999).
Nyman, U., et al., “Amelioration of collagen II-induced arthritis in rats by the type IV phosphodiesterase inhibitor rolipram,” Clin. Exp. Immunol, 108:415-419 (1997).
Gilhar, A., et al., “Antiproliferative effect of pentoxifylline on psoriatic and normal epidermis,” Acta Derm Venereol, 76:437-441 (1996).
Hanifin, Jon M., et al., “Type 4 phosphodiesterase inhibitors have clinical and in vivo anti-inflammatory effects in atopic dermatitis,” Journal of Investigative Dermatology, 107(1):51-56 (1996).
Diaz-Granados, Natalia et al., “Dextran sulfate sodium-induced colonic histopathology, but not altered epithelial ion transport, is reduced by inhibition of phosphodiesterase activity,” American Journal of Pathology, 156(6):2169-2177 (2000).
Dyke, Hazel J., et al., “The therapeautic potential of PDE4 inhibitors,” Exp. Opin. Invest. Drugs, 8(9):1301-1325 (1999).
Hartmann, Gunther et al., “Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice,” Journal of Pharmacology and Experimental Therapeutics, 292(1):22-30 (2000).
Stawiski, Marek A., et al., “Ro 20-1724: an agent that significantly improves psoriatic lesions in double-blind clinical trials,” The Journal of Investigative Dermatology, 73(4):261-263 (1979).
Teixeira, Mauro M., et al., “Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future?,” TiPS, 18:164-170 (1997).
Ross, Susan E., et al., “Suppression of TNF-α expression, inhibition of Th1 activity, and amerlioration of collagen-induced arthritis by rolipram,” Journal of Immunology, pp. 6253-6259 (1997).
Sekut, L., et al., “Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation,” Clin. Exp. Immunol, 100:126-132 (1995).
Nicholson, C. David, et al., “Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes,” TiPS, 12:19-27 (1991).
Solomons, T. W. G., Organic Chemistry, John Wiley & Sons, Inc., pp. 463-468, 485-486 (1978).
Aguilar Izquierdo Nuria
Dal Piaz Vittorio
Giovannoni Maria Paola
Vergelli Claudia
Berch Mark L.
Finnegan Henderson Farabow Garrett & Dunner LLP
Jaisle Cecilia M
Laboratorios Almirall S.A.
LandOfFree
Pyridazin-3(2 H )-one derivatives as PDE4 inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyridazin-3(2 H )-one derivatives as PDE4 inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyridazin-3(2 H )-one derivatives as PDE4 inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4022908